Arrowhead Appoints Patrick O’Brien as General Counsel

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical

company developing targeted RNAi therapeutics, today announced that it

has appointed Patrick O’Brien as General Counsel. In this role, Mr.

O’Brien will have overall responsibility to manage all of the Company’s

legal matters.

“Patrick will be an integral part of the Arrowhead management team,”

said Christopher Anzalone, Ph.D., Arrowhead’s President and Chief

Executive Officer. “His twenty year history of representing and advising

biopharmaceutical companies from multiple vantage points will be a great

asset as we move forward.”

Mr. O’Brien comes to Arrowhead from Shire where he served as Group Vice

President, Legal in Shire’s Boston office. Prior to that, he was Chief

Legal Officer for Shire’s regenerative medicine division. Mr. O’Brien

has also served as Assistant General Counsel for Johnson & Johnson and

Vice President, Law of its Centocor Ortho-Biotech business unit,

Regulatory Counsel at the U.S. Food and Drug Administration, and as

outside counsel to biopharmaceutical high technology companies while

engaged in private practice. He holds B.S. in Pharmacy, Pharm.D., and

J.D. degrees from the University of Arizona.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing

targeted RNAi therapeutics. The company is leveraging its proprietary

Dynamic Polyconjugate delivery platform to develop targeted drugs based

on the RNA interference mechanism that efficiently silences

disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic

hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1

antitrypsin deficiency, and partner-based programs in obesity and

oncology.

For more information please visit http://www.arrowheadresearch.com,

or follow us on Twitter @ArrowRes.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadresearch.com/alerts.cfm.

NASDAQ Notice

As an inducement to entering into employment with the Company, on

December 2, 2014, new employees of the Company were awarded an

“inducement” grant of options and restricted stock units (RSU) under

Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option entitles the

new employees to purchase, outside of the Company’s stockholder approved

equity incentive plans, an aggregate of up to 120,000 shares of the

Company’s common stock at an exercise price per share of $5.22, the last

reported closing price of the Company’s common stock on the date of

grant and 30,000 restricted stock units. The option vests and becomes

exercisable over a period of four years from the date of grant and the

RSUs vest annually in three equal installments.

Source: Arrowhead Research Corporation

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor

Relations:
The Trout Group
Lauren Glaser
646-378-2972
ir@arrowres.com
or
Media:
Russo

Partners
Martina Schwarzkopf, Ph.D.
212-845-4292
martina.schwarzkopf@russopartnersllc.com

Source: Arrowhead Research Corporation

News Provided by Acquire Media